CLEVELAND--(BUSINESS WIRE)--Nanosensor technology firm IdentifySensors Biologics has developed all new technology that detects COVID-19 RNA in saliva through newly developed electronic nanosensors, which significantly reduces error rates associated with chemical-based home tests. The company’s over-the-counter self-test, which can be performed entirely at home, is in final stages of development at Purdue University. (Purdue news release) The test – Check4-COVID™ – will require no prescription, no nasal swabs, no mailed samples or waiting in line. The test’s greatest advantage is its ability to accurately detect asymptomatic and early infections on a molecular level – a significant weakness in home tests recently approved. “Chemical-based home tests do not detect the virus on a genetic level and often miss early and asymptomatic cases,” said IdentifySensors CEO Gregory Hummer MD. “By the time someone gets sick and tested, the virus usually has already spread. Our test catches early infections and asymptomatic cases within minutes and without clinical intervention. This is a major breakthrough in managing the pandemic.”